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ABSTRACT
Primary splenic angiosarcoma is a rare, aggressive malig-
nant neoplasm arising from splenic vascular endothelium.
A 70-year-old woman presented with shortness of breath
and chest discomfort secondary to a left-sided pleural
effusion. A thoracentesis revealed a reactive effusion sus-
picious for malignancy. Splenic enlargement with hetero-
geneous enhancement was identified on CT of the abdo-
men. Laboratory findings at initial presentation revealed
mild anemia (10.5g/dL) with normal platelets (300  10
9/L).
Laparoscopic splenectomy was performed, and a primary
splenic angiosarcoma was discovered. After 2 rounds of
chemotherapy, a CT scan showed progressive disease
with metastasis to the liver and lung. The patient’s anti-
neoplastic regimen was switched to Ifosfamide and Doxo-
rubicin. She is currently alive with evidence of disease at
9 months but without further progression. Primary splenic
angiosarcoma is almost universally fatal despite treatment.
The best chance for survival is early diagnosis and prompt
splenectomy prior to splenic rupture.
Key Words: Hemangiosarcoma, Splenic cancer
INTRODUCTION
Primary splenic angiosarcomas are rare, aggressive malig-
nant neoplasms arising from splenic sinusoidal vascular
endothelium. First described by Langhans in 1879,1 it is
among the rarest types of neoplasm, with an estimated
annual incidence of 0.14 to 0.25 cases per million per-
sons.2,3 Splenectomy is thought to be the only intervention
that may result in long-term, disease-free survival. Primary
splenic angiosarcomas are associated with a very poor
prognosis, because they have proven to be highly refrac-
tory to adjuvant radiation and chemotherapy. Almost all
patients die within 12 months of diagnosis regardless of
treatment.2–4 Very few reviews are available to date in the
literature.2,3 A case report of this rare clinical entity and
complete review of the current literature are provided.
CASE REPORT
The patient is a 70-year-old woman who presented to her
primary care physician with shortness of breath and chest
discomfort secondary to a moderate left-sided pleural ef-
fusion. Her past medical history was significant for hyper-
lipidemia, hypertension, and papillary thyroid cancer
treated with surgery and postoperative radioiodine abla-
tion 18 years earlier. A thoracentesis was performed with
findings consistent with a reactive effusion and numerous
mesothelial cells admixed with inflammatory cells. The
suspicion of a neoplastic process remained high, and the
patient had a recurrence of the pleural effusion. A com-
puted tomography (CT) scan was done, demonstrating the
previously known effusion and splenomegaly. Splenic
enlargement with heterogeneous enhancement was iden-
tified (Figures 1A, 1B). The differential diagnosis was
infarct, hematoma, or metastatic mass lesion. Laboratory
findings at initial presentation revealed mild anemia
(10.5g/dL) with normal platelets (300  10
9/L).
After surgical consultation, we performed a hand-assisted
laparoscopic splenectomy. The patient was placed in the
right lateral position at a 45-degree angle with the table.
Access was gained just superior to the umbilicus, and 3
additional left subcostal ports were placed under direct
vision. The splenic flexure of the colon was taken down.
The inferior pole vessels of the spleen were dissected out
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CASE REPORTand taken with a vascular loaded linear endoscopic sta-
pler. The gastrosplenic ligament was then opened and
short gastric vessels taken with the ultrasonic shears. The
splenic hilum was then dissected out. Care was taken not
to violate the splenic capsule or the pancreatic paren-
chyma. The hilum and superior pole vessels were then
taken with a 60-mm vascular loaded stapler. An additional
hilar splenule had been identified and taken en bloc with
the specimen. The supraumbilical incision was then en-
larged to 9cm, and the GelPort hand access device (Ap-
plied Medical, Rancho Santa Margarita, CA) placed. With
the intraabdominal hand retracting the spleen, the remain-
ing diaphragmatic and retroperitoneal attachments were
taken down and the spleen bagged. The bagged spleen
(Figure 1C) was then removed intact through the GelPort
incision aided by stretching and retraction of the fascia
and skin. Pneumoperitoneum was then reestablished and
laparoscopic examination of the left upper quadrant and
liver performed. Hemostasis was secured, no additional
metastatic lesions were found, and the procedure termi-
nated. The patient tolerated the procedure well and had
an uneventful hospital course. On histological examina-
tion, the specimen was found to have marked pleomor-
phic and ovoid nuclei with eosinophilic globules through-
out the cytoplasm (Figure 2). The mitotic activity varied
from 0 to 3 mitotic figures per one high-power field
Figure 2. Splenic parenchyma is partially replaced by a spindle
cell neoplasm that forms abortive vascular lumina and contains
numerous extravasated erythrocytes.
Figure 1. (A) CT image coronal view of splenic mass; (B) CT image transverse view of splenic mass. (C) Gross specimen.
Primary Splenic Angiosarcoma, Hamid KS et al.
JSLS (2010)14:431–435 432(Figure 3). Approximately 5% to 10% of the neoplastic
cells expressed proliferation marker Ki-67 (Figure 4). The
neoplastic cells were all strongly positive for CD31 and
CD34. The majority of them were also strongly positive for
the vascular marker von Willebrand Factor, but they were
negative for CD8. Final pathology revealed a primary
splenic angiosarcoma metastatic to the hilar splenule. A
left liver biopsy was performed at the time of surgery and
was found to be free of disease.
The patient was started on an initial chemotherapy regi-
men of Gemcitabine HCl and Docetaxel. After 2 rounds of
treatment, a CT scan showed progressive disease with
metastasis to the liver and left lower lobe of the lung. The
patient’s chemotherapy regimen was switched to Ifosf-
amide and Doxorubicin, and she has not had further
progression of disease after 4 rounds of this second regi-
men. She is currently alive but with evidence of disease at
8 months following her initial presentation.
DISCUSSION
Primary angiosarcoma of the spleen is a rare and aggres-
sive malignant neoplasm arising from splenic vascular
endothelium and mesenchymal-derived elongated endo-
thelial cells lining the spleen’s spongy network of sinu-
soids. In general, angiosarcomas are rapidly proliferating,
highly infiltrating anaplastic cells that tend to recur locally,
spread widely, and have an increased rate of lymph node
and systemic metastases.2–8 Splenic angiosarcomas have
also shown a slight predilection for women, but no sexual
predilection has been found.3 They occur almost exclu-
sively after 40 years of age.2–5 Only 9 cases have been
reported in the pediatric literature to date.9
There are no specific clinical diagnostic guidelines for this
rare entity, but upper abdominal pain is the predominant
presenting symptom in more than 80% of cases. Constitu-
tional symptoms common in malignancy, such as fever,
fatigue, and weight loss, have also been observed but are
the initial symptoms less than 10% of the time.2,3,6–8 Upon
physical examination, splenomegaly is frequent, and a
palpable left upper quadrant mass can often be found.
Splenic rupture rates have been reported at 13% to 32%.
Anemia is the most common laboratory abnormality in
75% to 81% of cases, although 10% to 40% of patients have
thrombocytopenia; leukocytosis is often noted.2–4,6–9
The pathogenesis of splenic angiosarcomas is unknown.
A few patients have been described with splenic angio-
sarcomas many years after receiving radiation therapy for
other malignancies. However, no clear relationship with
radiation exposure has been established to date.10 Some
authors have hypothesized that primary splenic angiosar-
comas may be the result of malignant transformation of
other benign splenic tumors, such as hemangiomas, lym-
phangiomas, and hemangioendotheliomas.2,3,6,9,11 Tho-
rium dioxide, vinyl chloride, and arsenic have been im-
plicated in the formation of hepatic angiosarcomas, but no
Figure 3. Neoplastic cells expressing the Ki-67 proliferation
marker.
Figure 4. Mitotic figure (arrow).
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splenic angiosarcomas has been substantiated. Chemo-
therapy has also not been implicated as a potential cause
of angiosarcomas of the spleen.2–4,6–8
Patients with splenic angiosarcoma often have spleens
weighing 1000g.2 Macroscopically, there may be diffuse
involvement of the spleen and replacement of the entire
splenic parenchyma with tumor. Solitary masses are un-
common, and most tumors have usually undergone hem-
orrhage and necrosis. The histologic appearance of
splenic angiosarcomas is quite heterogeneous. Immuno-
histochemical investigations have suggested that primary
splenic angiosarcomas may arise from splenic sinus en-
dothelial cells.3,12 Thus, these tumors show at least a focal
vasoformative component, though it is usually the domi-
nant pattern.3,9 The tumor consists of disorganized anas-
tomosing vascular channels lined by large, atypical endo-
thelial cells with significant irregular, hyperchromatic
nuclei. Poorly differentiated areas have sarcomatous fea-
tures, whereas well-differentiated regions appear very
similar to the sinuses of the spleen. Mark et al13 found that
histological appearance or grade is not related to out-
come, because well-differentiated lesions can behave as
aggressively as poorly differentiated ones. In a multivar-
iate analysis of 55 cases of angiosarcoma, Naka et al14
determined that mitotic counts and tumor size were
prognostic factors. Due to their variable histology, ma-
lignant vascular neoplasms of the spleen may be con-
fused with benign vascular tumors or malignant nonva-
scular tumors.3,4
Metastases occur in 69% to 100% of cases of splenic
angiosarcoma.2,3,10,15 Neuhauser et al3 reported the rates
of metastases as 89% to the liver, 78% to the lungs, 56% to
lymph nodes, and 44% to bone. Falk et al2 found rates of
metastases as 41% to the liver, 22% to bone or its marrow,
and 3% to lymph nodes. Metastases were not necessarily
associated with higher mortality or accelerated death in
their study.
The radiologic features of splenic angiosarcomas vary
with imaging modality. Ultrasound, CT, and magnetic res-
onance imaging (MRI) all display well evidence of spleno-
megaly. On ultrasound, a complex mass with heteroge-
neous echotexture is the most common finding. Areas of
necrosis and hemorrhage are frequently noted as cystic
areas within the mass.4 On CT scans, the most common
finding is an ill-defined heterogeneously enhancing
splenic mass with areas of necrosis. In the event of acute
rupture, hemorrhage will appear hyperattenuated on un-
enhanced images. There is no particular pattern of calci-
fication associated with splenic angiosarcoma, but areas
of hypervascular metastases to the liver, lungs, bones, and
lymphatic system are well demonstrated on CT.3–5 On
MRI, T1- and T2-weighted pulse sequences show areas of
increased and decreased signal intensity that are consis-
tent with necrosis and the presence of hemorrhage. MRI
with contrast enhancement shows heterogeneous en-
hancement within the tumor reflective of solid tumor with
areas of necrosis.4,5 Regardless of imaging modality, ra-
diologic diagnosis of splenic angiosarcoma remains highly
challenging due to the great overlap with other vascular
splenic tumors, such as hemangiomas, littoral cell angio-
mas, lymphangiomas, hemangiopericytomas, and epithe-
lioid vascular tumors that may all mimic it. Additionally,
other malignant tumors must be considered in the differ-
ential diagnosis, such as lymphoma, metastatic disease,
and other rare sarcomas.5
Splenic angiosarcoma is usually treated with splenectomy,
although it is rarely curative due to the aggressive and
metastatic nature of the disease.2,3,10,11 In a study of 28
patients with primary splenic angiosarcoma done by Neu-
hauser et al,3 only 2 patients were alive at last follow-up,
one with evidence of disease at 8 years who had received
combination chemotherapy and radiation therapy and
one without evidence of disease at 10 years who had been
treated by splenectomy alone. Of the remaining 26 pa-
tients, one was lost to follow-up, and the other 25 died of
disseminated disease. There was no statistically significant
correlation between survival and nonsurgical treatment
rendered (chemotherapy, radiation, or combination). The
longest recorded duration of survival in a patient with
primary splenic angiosarcoma is 16 years in a pediatric
patient who was treated with splenectomy alone at 7 years
of age.9 At this time, there is no convincing evidence to
suggest a clinical benefit of chemotherapy in the treatment
of splenic angiosarcoma.3,10 Splenectomy prior to rupture
has been demonstrated to increase length of survival com-
pared with splenectomy after rupture.2 Montemayor and
Caggiano16 confirmed this finding and showed that mean
survival times of splenectomy prior to rupture versus after
rupture were 14.4 and 4.4 months, respectively.
CONCLUSION
Primary splenic angiosarcoma is a rare and aggressive
malignancy found primarily in adults over 40 years of age
and almost universally fatal despite treatment. Its patho-
genesis remains unclear, and its clinical and radiologic
diagnoses are challenging. The diagnosis should be sus-
pected in any patient with splenomegaly and anemia of
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torically been unsuccessful in improving outcome in this
patient population. More evaluation of these options will
be needed due to limited experience thus far. The best
chance for survival is early diagnosis and prompt splenec-
tomy prior to splenic rupture.
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